Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Werewolf Therapeutics (HOWL) Net Margin (2022 - 2024)

Werewolf Therapeutics (HOWL) has disclosed Net Margin for 3 consecutive years, with 1601.84% as the latest value for Q2 2024.

  • Quarterly Net Margin fell 153906.0% to 1601.84% in Q2 2024 from the year-ago period, while the trailing twelve-month figure was 6442.87% through Mar 2025, down 618677.0% year-over-year, with the annual reading at 3797.19% for FY2024, 361554.0% down from the prior year.
  • Net Margin for Q2 2024 was 1601.84% at Werewolf Therapeutics, up from 2182.21% in the prior quarter.
  • The five-year high for Net Margin was 62.78% in Q2 2023, with the low at 2182.21% in Q1 2024.
  • Average Net Margin over 3 years is 642.9%, with a median of 243.64% recorded in 2023.
  • The sharpest move saw Net Margin skyrocketed 28906bps in 2023, then plummeted -193857bps in 2024.
  • Over 3 years, Net Margin stood at 163.81% in 2022, then crashed by -388bps to 799.27% in 2023, then tumbled by -100bps to 1601.84% in 2024.
  • According to Business Quant data, Net Margin over the past three periods came in at 1601.84%, 2182.21%, and 799.27% for Q2 2024, Q1 2024, and Q4 2023 respectively.